

Protocol for hPSC Differentiation to Skeletal Myotubes

Figure 1. Genea Biocells Skeletal Muscle differentiation as per Caron et. Al. 2016.

Reagents:

kel047 168E0 2T 04W0 1 3axs

-
-
-
-

And

-



:

Plate/Flask Format			

Protocol Index

2.

Cat #	Description

Academic Inquiries-US and Europe:

Japan:

Stage I – Conversion of human PSC to myogenic precursors

1.1. _____

1.1.1.

1.1.2.

1.1.3.

1.1.4.

1.1.5.

1.1.6.

Note: Successful skeletal muscle differentiation has been observed in difficult cell lines plated at densities from 2500 to 10,000 cells/cm²


Note: Growth formats smaller than 12 well plates are not recommended for Stage I.

1.1.7.

1.1.8.

1.1.9.

1.2. _____



Stage II – Conversion of Myogenic Precursors to Myoblasts

1.3. _____

1.3.1.

1.3.2.

1.3.3.

1.3.4.

~~1.3.5.~~


1.3.6.

1.3.7.

1.3.8.

1.3.9.

1.4. _____



Stage III – Differentiation of Myoblasts to post mitotic Myotubes

1.5. _____

1.5.1. _____

1.5.1.1.

Note: Myoblasts are not dissociated at this stage; ensure the cells have formed a confluent monolayer to fully differentiate into Myotubes

Note: Use of Myotube/Myotube Fusion Medium will depend on end user assay requirements

1.5.1.2.

1.5.2. _____

1.5.2.1.

1.5.2.2.

1.5.2.3.

1.5.2.4.

1.5.2.5.

1.5.2.6.


1.5.2.7.

1.5.2.8.

1.5.2.9.

1.5.2.10.

1.5.3. _____



	<p>Cell Line 1</p>	
	<p>Cell Line 2</p>	
<p>Myotubes in SkM. Myotube Medium (SKM-03)</p>	<p>Stage 3</p>	<p>Myotubes in SkM. Myotube Fusion Medium (SKM-03+)</p>

	<p>Stage 3</p>	
<p>Myotubes in SkM. Myotube Medium (SKM-03)</p>	<p>Stage 3</p>	<p>Myotubes in SkM. Myotube Fusion Medium (SKM-03+)</p>